Abstract
Over the last years, ligands for angiotensin II subtype 1 receptor (AT1R) have been developed as an alternative to the use of angiotensin-converting enzyme (ACE) inhibitors for controlling high blood pressure. Radiolabeled versions of these ligands have proven vital to the development of more potent and specific drugs for the treatment of hypertension. Imaging studies using radiolabeled AT1R ligands have also elucidated the role these receptors play in angiogenesis as well as in various disease states beyond hypertension.
Keywords: Angiotensin, AT1, carbon-11, hypertension, iodine-125, Losartan, radioligand, tritium, Angiotensin II, (AT1) Receptor, angiotensin-converting enzyme (ACE), renin-angiotensin system (RAS), ACE inhibitors, Physiological regulation, atherosclerosis, renal fibrosis, myocardial remodeling, carcinogenesis, arterial hypertension, Fibrocyte accumulation, extracellular matrix (ECM), protein kinases (MAPKs), renin-angiotensin system, ANG II PEPTIDE ANALOGS, Losartan derivatives, blood-brain barrier (BBB), Candesartan, 18F-labeled AT1 antagonist, Eprosartan, Irbesartan, Telmisartan, Valsartan, Olmesartan, SK-1080, KR31173
Current Topics in Medicinal Chemistry
Title: Radioligands for the Angiotensin II Subtype 1 (AT1) Receptor
Volume: 10 Issue: 16
Author(s): William B. Mathews and Zsolt Szabo
Affiliation:
Keywords: Angiotensin, AT1, carbon-11, hypertension, iodine-125, Losartan, radioligand, tritium, Angiotensin II, (AT1) Receptor, angiotensin-converting enzyme (ACE), renin-angiotensin system (RAS), ACE inhibitors, Physiological regulation, atherosclerosis, renal fibrosis, myocardial remodeling, carcinogenesis, arterial hypertension, Fibrocyte accumulation, extracellular matrix (ECM), protein kinases (MAPKs), renin-angiotensin system, ANG II PEPTIDE ANALOGS, Losartan derivatives, blood-brain barrier (BBB), Candesartan, 18F-labeled AT1 antagonist, Eprosartan, Irbesartan, Telmisartan, Valsartan, Olmesartan, SK-1080, KR31173
Abstract: Over the last years, ligands for angiotensin II subtype 1 receptor (AT1R) have been developed as an alternative to the use of angiotensin-converting enzyme (ACE) inhibitors for controlling high blood pressure. Radiolabeled versions of these ligands have proven vital to the development of more potent and specific drugs for the treatment of hypertension. Imaging studies using radiolabeled AT1R ligands have also elucidated the role these receptors play in angiogenesis as well as in various disease states beyond hypertension.
Export Options
About this article
Cite this article as:
B. Mathews William and Szabo Zsolt, Radioligands for the Angiotensin II Subtype 1 (AT1) Receptor, Current Topics in Medicinal Chemistry 2010; 10 (16) . https://dx.doi.org/10.2174/156802610793176729
DOI https://dx.doi.org/10.2174/156802610793176729 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Myocardial Revascularization Strategies in Diabetic Patients with Multi-Vessel Disease: CABG vs DES-Based PCI
Current Pharmaceutical Design The IL23/Th17 Pathway as a Therapeutic Target in Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Seasonal and Perennial Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Pharmacogenetics in Methadone Therapy
Current Pharmacogenomics and Personalized Medicine Evaluation of Cardiac Scan in Diagnosing Coronary-artery Disease
Current Medical Imaging Risk for Cervical Intraepithelial Neoplasia in Systemic Lupus Erythematosus is not Related to Disease Severity
Current Rheumatology Reviews Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries
Current Pharmacogenomics and Personalized Medicine New Biochemical Markers in Acute Coronary Syndromes
Current Medicinal Chemistry Expression and Role of the Calcium-Sensing Receptor in the Blood Vessel Wall
Current Pharmaceutical Biotechnology Determining Effective Diabetic Care; A Multicentre - Longitudinal Interventional Study
Current Pharmaceutical Design Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews Statins in Diabetes Mellitus
Current Pharmaceutical Design Implications of Angiotensin II in Central Nervous System on Exercise Performance
Current Protein & Peptide Science Oxidative Stress and Psychological Disorders
Current Neuropharmacology Regulation of Catechins in Uric Acid Metabolism Disorder Related Human Diseases
Mini-Reviews in Medicinal Chemistry Synthesis and Biological Interest of Structured Docosahexaenoic Acid–Containing Triacylglycerols and Phospholipids
Current Organic Chemistry Chemometric Assisted Simultaneous Analysis of Verapamil Hydrochloride, Gliclazide and Simvastatin in Bulk Drug and Fixed Dose Combinatinos (polypill) - A Futuristic Approach
Current Analytical Chemistry Non-invasive Estimation of Aortic Blood Pressures: A Close Look at Current Devices and Methods
Current Pharmaceutical Design Pathogenesis and Management of Hypertension after Kidney Transplantation
Current Hypertension Reviews